carefirst bluechoice glp 1 coverage What's Changed, What's New FEHB- CareFirst and GLP-1 meds

In late 2024, tirzepatide (Zepbound) became the first GLP-1 and first medication to be approved for sleep apnea

From high-fat foods that worsen gastrointestinal side effects to medication interactions that may affect absorption or increase hypoglycemia risk, patients need clear guidance on navigating treatment

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

Ondansetron and semaglutide do not have direct pharmacokinetic interactionsthey are metabolized through different pathways and do not compete for the same enzymes

Romero-Falcon A, de la Santa-Belda E, Garcia-Contreras R, Varela JM: A case of valproate-associated hepatotoxicity treated with L-carnitine